A new trading day began on Monday, with Fate Therapeutics Inc (NASDAQ: FATE) stock price up 8.30% from the previous day of trading, before settling in for the closing price of $2.65. FATE’s price has ranged from $1.63 to $8.83 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 87.14%. Meanwhile, its annual earnings per share averaged -0.05%. With a float of $94.87 million, this company’s outstanding shares have now reached $98.63 million.
Let’s determine the extent of company efficiency that accounts for 181 employees. In terms of profitability, gross margin is -55.61%, operating margin of -1587.28%, and the pretax margin is -1426.67%.
Fate Therapeutics Inc (FATE) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Fate Therapeutics Inc is 16.69%, while institutional ownership is 93.09%. The most recent insider transaction that took place on Aug 06 ’24, was worth 2,678. In this transaction Director of this company sold 633 shares at a rate of $4.23, taking the stock ownership to the 8,669 shares. Before that another transaction happened on Aug 06 ’24, when Company’s Director proposed sale 633 for $4.23, making the entire transaction worth $2,678.
Fate Therapeutics Inc (FATE) Earnings and Forecasts
In its latest quarterly report, released on 6/30/2024, the company reported earnings of -0.46 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.44 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -0.05% per share during the next fiscal year.
Fate Therapeutics Inc (NASDAQ: FATE) Trading Performance Indicators
Here are Fate Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 9.18. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 26.53.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.71, a number that is poised to hit -0.42 in the next quarter and is forecasted to reach -1.65 in one year’s time.
Technical Analysis of Fate Therapeutics Inc (FATE)
Looking closely at Fate Therapeutics Inc (NASDAQ: FATE), its last 5-days average volume was 1.39 million, which is a drop from its year-to-date volume of 2.21 million. As of the previous 9 days, the stock’s Stochastic %D was 12.41%. Additionally, its Average True Range was 0.21.
During the past 100 days, Fate Therapeutics Inc’s (FATE) raw stochastic average was set at 7.01%, which indicates a significant decrease from 33.82% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 66.76% in the past 14 days, which was lower than the 80.93% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.44, while its 200-day Moving Average is $4.66. However, in the short run, Fate Therapeutics Inc’s stock first resistance to watch stands at $2.94. Second resistance stands at $3.00. The third major resistance level sits at $3.14. If the price goes on to break the first support level at $2.74, it is likely to go to the next support level at $2.60. Should the price break the second support level, the third support level stands at $2.54.
Fate Therapeutics Inc (NASDAQ: FATE) Key Stats
With a market capitalization of 326.84 million, the company has a total of 113,832K Shares Outstanding. Currently, annual sales are 63,530 K while annual income is -160,930 K. The company’s previous quarter sales were 6,770 K while its latest quarter income was -38,430 K.
